2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Surgical, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

6158 Improving timely referral and care coordination for CAR T-cell therapy through a standardized referral blueprint: A multicenter quality improvement initiative

Marc S. Hoffmann, MD, Caron Jacobson, MD, MMSc2, Muhamad Alhaj Moustafa, MD, MS3, Emily Zyborowicz, MPH4, Jeffrey Carter5, Chelsie Anderson Chadha6, Laura Simone, PhD7, Shelby Sullivan, PharmD8
1 University of Kansas Medical Center, Kansas City, Kansas, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Mayo Clinic, Jacksonville, Florida, United States
4 PRIME Education, New York, New York, United States
5 PRIME Education, New York, New York, United States
6 PRIME Education, New York, New York, United States
7 PRIME Education, New York, New York, United States
8 PRIME Education, New York, New York, United States

Background

Timely referral and coordinated care between community oncology clinics and chimeric antigen receptor (CAR) T-cell centers remain significant challenges for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Delays in identifying eligible patients, inconsistent communication pathways, and variability in referral workflows may limit access to CAR T-cell therapy. This quality improvement (QI) initiative focused on the development and adoption of a CAR T-cell Referral Blueprint to facilitate optimize referrals and interprofessional care coordination between academic CAR T-cell centers and regional community oncology clinics.

Methods
Baseline surveys of clinical teams from the enrolled 3 CAR T-cell centers and 5 regional community oncology clinics characterized existing referral workflows and barriers, while an expert Steering Committee informed development of a standardized CAR T-cell Referral Blueprint. Five 1.0-hour live, team-based audit-feedback (AF) sessions were conducted across enrolled centers, involving 50 providers who reviewed clinic-specific gaps and developed targeted action plans to optimize referral pathways and care coordination. Follow-up surveys completed by clinic champions (N=8) evaluated practice change and integration of the Referral Blueprint into clinical practice. Survey instruments assessed knowledge, confidence, referral practices, and reported system-level process improvements.

Results
Baseline barriers to referral and care coordination included suboptimal clinic referral processes (26%), patient resistance to CAR T-cell therapy (26%), uncertainty regarding patient eligibility (23%), maintaining patient stability during bridging therapy (23%), and limited experience managing patients after CAR T-cell therapy (20%). Educational outcomes demonstrated meaningful improvements in participants’ knowledge and clinical competence related to evidence-based use of CAR T-cell therapy for DLBCL and FL. Providers showed increased ability to appropriately identify approved CAR T-cell treatment options (34% to 70%) and determine appropriate timing of therapy across disease settings (20% to 60%). High/very high confidence in employing interprofessional strategies to improve referral, communication, and care coordination increased from 34% pre-activity to 68% post-activity.

Participants identified strategies needed to improve referral pathways, including earlier specialty consultation, standardized surveillance templates, referral checklists, and improved communication between community clinics and CAR T-cell centers. Post-activity, participants planned to use the CAR T-cell Referral Blueprint resource to improve identification of eligible patients for referral (36%), improve referral protocols/workflows (22%), and increase staff awareness of referral processes (24%).

Follow-up surveys completed by clinic champions (N = 8) demonstrated sustained practice change. Fifty percent reported significant improvement in communication effectiveness between community clinics and CAR T-cell centers, while 63% reported increased early identification of eligible patients for CAR T-cell therapy following participation in the initiative. Areas of greatest improvement included early identification of eligible patients and coordination with referral centers. Teams described implementing updated referral protocols, earlier referral practices, telehealth integration, standardized checklists, and nurse-led coordination processes to streamline care transitions. These changes resulted in 38% of clinics reporting 50% or more referrals of eligible patients with R/R DLBCL and FL for CAR T-cell therapy.

Conclusions
This QI initiative identified persistent barriers to CAR T-cell referral and care coordination for patients with R/R DLBCL and FL while demonstrating that structured AF sessions and a standardized Referral Blueprint can improve provider knowledge, interprofessional collaboration, and referral workflows. Participating clinics reported meaningful improvements in patient identification, communication, and coordination with CAR T-cell centers, supporting broader adoption of standardized referral strategies to enhance timely access to CAR T-cell therapy.

Study Sponsor Statement
The study supported was funded by an educational grant from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation, who had no role in the study design, execution, analysis, or reporting.

Marc S. Hoffmann, MD: Genmab - Honoraria; Genentech - Research Funding; ADC Therapeutics - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); BeOne Medicines, Ltd - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)